Global CAR T Cell Therapy Market is forecasted to be growing at 53% till 2025: Sheer Analytics and Insights

The global CAR T Cell therapy market in terms of revenue is expected to go rapidly in terms of revenue generation by 2025 at a CAGR of 53% from 2018 to 2025 as per new market research titled Global CAR T cell therapy market (By Targeted Antigen – HER1, HER2, CD19, CD20, CD22, CD30, CD33, GD2, MESO And EGFRVIII, By Treatment - Non-Hodgkin Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Acute Lymphoblastic Leukemia (ALL), Multiple Myeloma, Acute Myeloid Leukemia (AML), Breast Cancer, Pancreatic Cancer, Neuroblastoma (NB), Colon Cancer And Hepatocellular Carcinoma (HCC)) – Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2017 – 2025

Read Full Report @ https://www.sheeranalyticsandinsights.com/market-report-research/car-t-cell-therapy-market-21

The foundation for many years in cancer treatment were chemotherapy, surgery, and radiation therapy. In the past few years it has been witnessed that emergence of immunotherapy that enlist and strengthen the power of the immune system in a patient so they can attack tumours. They are also popularly known as the “fifth pillar” of treating cancer. Moreover, now, doctors have started offering the CAR T cell therapy which is a new form of treating cancer.

What is CAR T cell therapy? Let’s get to know about this in details. It is immunotherapy commonly known as the adoptive cell therapy. The T-cells is a kind of white blood cell which is extracted by the doctors from the blood of the patient and then an artificial receptor is added to their surface. This receptor acts like the “heat-seeking missile” which helps the modified cells in the production of a chemical that that has the ability to kill cancer. once they are implemented back into the body of the patient through and IV, they start multiplying and attack the tumour cells.

The CAR T cell can be called as a type of antibody that has the ability to induce modular-fusion protein, which have extra cellular specific binding domain. It has been possible for this treatment to come-up against recurrence option for blood cancer and other types of carcinogenic cases. Today, CAR T cell in the carcinogenic therapeutics have become a boon for the healthcare industry. This have become possible for the many companies who have started investing in the CAR T cell therapy which have increased the demand of the market. Presently, the most successful of them all is the CD19 antigen and this is used for the treatment of acute lymphoblastic leukemia (ALL). It has also been approved by the Food and Drug Administration (FDA) and it is the first genetic engineering that is based on Kymriah (tisagenlecleucel) by Novartis AG. By the usage of the CAR T cell there are various clinal trials which are on process that can combat other types of tumours and acute myeloid leukomia.

The CAR T cell therapy market is booming owing to the increase of cancer cases. Moreover, this field is also advancing technologically which is creating huge potential for the growth of this market. However, the therapy packages of this treatment is huge and the longer period of their clinical trails is proving to be an obstacle for the growth of the CAR T cell market.

Download the sample report @ https://www.sheeranalyticsandinsights.com/request-sample/2/1/111/5

The CAR T cell market is segmented by its regions into North America, Latin America, Europe, Middle East & Africa, and Asia Pacific. However, Europe and North America dominates the market. The CAR T cell therapy’s demand over here is increasing rapidly mainly because of the rising prevalence of disease, increasing rate of geriatric population, world class diagnosis techniques, and growing awareness among the people. The market is driven by the rising awareness regarding cancer among the people, the advancement of diagnosis laboratories, and the initiatives that has to be taken by the government to spread awareness among the people.

In the recent market research report that was published by Sheer Analytics and Pvt. Ltd. Regarding the global CAR T cell therapy market the global CAR T cell therapy market has been categorized on the basis of targeted antigen, treatment and by geographical boundaries.
The targeted segment includes– HER1, HER2, CD19, CD20, CD22, CD30, CD33, GD2, MESO and EGFRvIII; the CD19 section is predicted to grab the major share of the global CAR T cell therapy market due to its highest success rate in detecting and treating acute lymphoblastic leukemia (ALL).Treatment type segment includes non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), multiple myeloma, acute myeloid leukemia (AML), breast cancer, pancreatic cancer, neuroblastoma (NB), colon cancer and hepatocellular carcinoma (HCC).Here, the acute lymphoblastic leukemia group is dominating the other diseases.

Send request for brochure @ https://www.sheeranalyticsandinsights.com/request-brochure/2/1/111/2

Ceylad, a clinical biopharmaceutical company has focused on the development of CAR T cell therapies, and they have announced that the U.S. Food and Drug Administration (FDA) have accepted the company’s Investigational New Drug (IND) application for CYAD-101. This will be the first non-gene edited allogenic clinical program.
The CEO of Ceylad, Dr. Christian Homsy told: “We are pleased to have achieved this important milestone. Celyad is the first company clinically evaluating a non-gene edited CAR-T candidate, which, we believe, offers significant advantages over gene edited approaches. Our non-gene edited program consists of a family of technologies aimed at reducing or eliminating T cell receptor (TCR) signaling without requiring genetic manipulation. CYAD-101 is part of a robust clinical development plan, establishing the foundations of next generation CAR-T products.”

The major companies operating in the global CAR T cell therapy market are Novartis International AG, Kite Pharma Inc., Juno Therapeutics, Cellectis, Bellicum Pharmaceuticals Inc. and Celgene Corporation among others.

Global CAR T Cell Therapy Market: By Targeted Antigen
• HER1
• HER2
• CD19
• CD20
• CD22
• CD30
• CD33
• GD2
• MESO and
• EGFRvIII

Global CAR T Cell Therapy Market: By Treatment
• Non-Hodgkin lymphoma (NHL)
• Chronic lymphocytic leukemia (CLL)
• Acute lymphoblastic leukemia (ALL)
• Multiple myeloma
• Acute myeloid leukemia (AML)
• Breast cancer
• Pancreatic cancer
• Neuroblastoma (NB)
• Colon cancer and
• Hepatocellular carcinoma (HCC)

Global CAR T Cell Therapy Market: By Geography

North America
• U.S.
• Canada
• Mexico

Europe
• U.K.
• Italy
• France
• Germany
• Russia
• Spain
• Rest of Europe

Asia Pacific
• India
• China
• Japan
• Australia
• Rest of Asia Pacific

Middle East and Africa
• GCC
• South Africa
• Rest of Middle East and Africa

Latin America
• Brazil
• Rest of Latin America

What can you find out in the CAR T cell therapy market report:
1. What is CAR T Cell Therapy?
2. What is Cancer Immunotherapy?
3. What is the global CAR T market size?
4. What is global cancer immunotherapy market size?
5. Which are driving factors behind the global CAR T cell therapy market?
6. What are the market trends and forecast for CAR T cell therapy market?
7. What does market research and analysis based on segmentation of CAR T market by targeted antigen say about global trends and forecasts?
8. What does market research and analysis based on segmentation of CAR T market by treatment say about global trends and forecasts?
9. What does market research and analysis based on segmentation of CAR T market by geography say about global trends and forecasts?
10. Which are the major CAR T therapy companies operating globally?

Table of content
1 INTRODUCTION
1.1 MARKET SEGMENTATION
2 RESEARCH METHODOLOGY
2.1 ECOSYSTEM OF GLOBAL CAR T-CELL THERAPYMARKET
2.2 TOP-DOWN APPROACH
2.3 BOTTOM-UP APPROACH
2.4 ASSUMPTIONS
3 EXECUTIVE SUMMARY
3.1 GLOBAL CAR T-CELL THERAPYMARKET SNAPSHOT
4 MARKET OVERVIEW
4.1 INTRODUCTION
4.2 KEY TREND ANALYSIS
4.3 PORTERS FIVE FORCE ANALYSIS
4.4 VALUE CHAIN ANALYSIS
5 GLOBAL CAR T-CELL THERAPYMARKET, BY TARGETED ANTIGEN
5.1 OVERVIEW
5.2 HER1
5.3 HER2
5.4 CD19
5.5 CD20
5.6 CD22
5.7 CD30
5.8 CD33
5.9 GD2
5.10 MESO AND
5.11 EGFRVIII
6 GLOBAL CAR T-CELL THERAPY MARKET, BY TREATMENT
6.1 OVERVIEW
6.2 NON-HODGKIN LYMPHOMA (NHL)
6.3 CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
6.4 ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
6.5 MULTIPLE MYELOMA
6.6 ACUTE MYELOID LEUKEMIA (AML)
6.7 BREAST CANCER
6.8 PANCREATIC CANCER
6.9 NEUROBLASTOMA (NB)
6.10 COLON CANCER AND
6.11 HEPATOCELLULAR CARCINOMA (HCC)
7 GLOBAL CAR T-CELL THERAPY MARKET, BY GEOGRAPHY
7.1 NORTH AMERICA
7.1.1 MARKET DYNAMICS
7.1.2 U.S.
7.1.3 CANADA
7.1.4 MEXICO
7.2 EUROPE
7.2.1 MARKET DYNAMICS
7.2.2 U.K.
7.2.3 ITALY
7.2.4 FRANCE
7.2.5 GERMANY
7.2.6 RUSSIA
7.2.7 SPAIN
7.2.8 REST OF EUROPE
7.3 ASIA PACIFIC
7.3.1 MARKET DYNAMICS
7.3.2 INDIA
7.3.3 CHINA
7.3.4 JAPAN
7.3.5 AUSTRALIA
7.3.6 REST OF ASIA PACIFIC
7.4 MIDDLE EAST AND AFRICA
7.4.1 MARKET DYNAMICS
7.4.2 GCC
7.4.3 SOUTH AFRICA
7.4.4 REST OF MIDDLE EAST AND AFRICA
7.5 LATIN AMERICA
7.5.1 MARKET DYNAMICS
7.5.2 BRAZIL
7.5.3 REST OF LATIN AMERICA
8 COMPETATIVE LANDSCAPE
8.1 OVERVIEW
8.2 MARKET SHARE ANALYSIS
8.3 PATENT ANALYSIS
9 GLOBAL CAR T-CELL THERAPY MARKET, BY COMPANY
9.1 INTRODUCTION
9.2 NOVARTIS INTERNATIONAL AG
9.2.1 BUSINESS OVERVIEW
9.2.2 PRODUCT & SERVICES
9.2.3 KEY STRATEGY
9.2.4 RECENT DEVELOPMENTS
9.2.5 SWOT ANALYSIS
9.3 KITE PHARMA INC.
9.3.1 BUSINESS OVERVIEW
9.3.2 PRODUCT & SERVICES
9.3.3 KEY STRATEGY
9.3.4 RECENT DEVELOPMENTS
9.3.5 SWOT ANALYSIS
9.4 JUNO THERAPEUTICS
9.4.1 BUSINESS OVERVIEW
9.4.2 PRODUCT & SERVICES
9.4.3 KEY STRATEGY
9.4.4 RECENT DEVELOPMENTS
9.4.5 SWOT ANALYSIS
9.5 CELLECTIS
9.5.1 BUSINESS OVERVIEW
9.5.2 PRODUCT & SERVICES
9.5.3 KEY STRATEGY
9.5.4 RECENT DEVELOPMENTS
9.5.5 SWOT ANALYSIS
9.6 BELLICUM PHARMACEUTICALS INC. AND
9.6.1 BUSINESS OVERVIEW
9.6.2 PRODUCT & SERVICES
9.6.3 KEY STRATEGY
9.6.4 RECENT DEVELOPMENTS
9.6.5 SWOT ANALYSIS
9.7 CELGENE CORPORATION
9.7.1 BUSINESS OVERVIEW
9.7.2 PRODUCT & SERVICES
9.7.3 KEY STRATEGY
9.7.4 RECENT DEVELOPMENTS
9.7.5 SWOT ANALYSIS

Key Tables and Figures Provided:

LIST OF TABLES
TABLE 1 GLOBAL CAR T-CELL THERAPY MARKET SIZE, 2017-2025 (USD MN)
TABLE 2 GLOBAL CAR T-CELL THERAPY MARKET, BY TARGETED ANTIGEN
TABLE 3 GLOBAL CAR T-CELL THERAPY MARKET, BY TREATMENT
TABLE 4 NEW PRODUCT LAUNCHES, 2014-2016
TABLE 5 NORTH AMERICA CAR T-CELL THERAPY MARKET SIZE, 2017-2025 (USD MN)
TABLE 6 NORTH AMERICA CAR T-CELL THERAPY MARKET, BY TARGETED ANTIGEN
TABLE 7 NORTH AMERICA CAR T-CELL THERAPY MARKET, BY TREATMENT
TABLE 8 NORTH AMERICACAR T-CELL THERAPYMARKET, BY COUNTRY
TABLE 9 EUROPE CAR T-CELL THERAPY MARKET SIZE, 2017-2025 (USD MN)
TABLE 10 EUROPECAR T-CELL THERAPY MARKET, BY TARGETED ANTIGEN
TABLE 11 EUROPE CAR T-CELL THERAPY MARKET, BY TREATMENT
TABLE 12 EUROPECAR T-CELL THERAPYMARKET, BY COUNTRY
TABLE 13 ASIA PACIFIC CAR T-CELL THERAPYMARKET SIZE, 2017-2025 (USD MN)
TABLE 14 ASIA PACIFIC CAR T-CELL THERAPY MARKET, BY TARGETED ANTIGEN
TABLE 15 ASIA PACIFIC CAR T-CELL THERAPY MARKET, BY TREATMENT
TABLE 16 ASIA PACIFICCAR T-CELL THERAPYMARKET, BY COUNTRY
TABLE 17 MIDDLE EAST AND AFRICA CAR T-CELL THERAPY MARKET SIZE, 2017-2025 (USD MN)
TABLE 18 MIDDLE EAST AND AFRICA CAR T-CELL THERAPY MARKET, BY TARGETED ANTIGEN
TABLE 19 MIDDLE EAST AND AFRICA CAR T-CELL THERAPY MARKET, BY TREATMENT
TABLE 20 MIDDLE EAST AND AFRICACAR T-CELL THERAPYMARKET, BY COUNTRY
TABLE 21 LATIN AMERICA CAR T-CELL THERAPYMARKET SIZE, 2017-2025 (USD MN)
TABLE 22 LATIN AMERICA CAR T-CELL THERAPY MARKET, BY TARGETED ANTIGEN
TABLE 23 LATIN AMERICA CAR T-CELL THERAPY MARKET, BY TREATMENT
TABLE 24 LATIN AMERICACAR T-CELL THERAPYMARKET, BY COUNTRY

LIST OF FIGURES
FIGURE 1 GLOBAL CAR T-CELL THERAPYMARKET SEGMENT
FIGURE 2 GLOBAL CAR T-CELL THERAPYMARKET INTEGRATED ECOSYSTEM
FIGURE 3 TOP-DOWN APPROACH
FIGURE 4 BOTTOM-UP APPROACH
FIGURE 5 NORTH AMERICA CAR T-CELL THERAPY MARKET SNAPSHOT
FIGURE 6 EUROPE CAR T-CELL THERAPY MARKET SNAPSHOT
FIGURE 7 ASIA PACIFIC CAR T-CELL THERAPYMARKET SNAPSHOT
FIGURE 8 MIDDLE EAST AND AFRICACAR T-CELL THERAPY MARKET SNAPSHOT
FIGURE 9 LATIN AMERICACAR T-CELL THERAPY MARKET SNAPSHOT
FIGURE 10 SWOT ANALYSIS OF NOVARTIS INTERNATIONAL AG.
FIGURE 11 SWOT ANALYSIS OF KITE PHARMA INC.
FIGURE 12 SWOT ANALYSIS OF JUNO THERAPEUTICS
FIGURE 13 SWOT ANALYSIS OF CELLECTIS
FIGURE 14 SWOT ANALYSIS OF BELLICUM PHARMACEUTICALS INC.
FIGURE 15 SWOT ANALYSIS OF CELGENE CORPORATION

Sheer Analytics and Insights Pvt. Ltd. is among the leading market research organizations providing the best B2B researches on various niches. Currently servicing 2000+ clients worldwide, our analysts and marketing team are continually tracking global markets having high growth prospect.

Sheer Analytics and Insights Pvt. Ltd.
Registered office:
RDB Boulevard,
8th Floor,
Plot K 1,
Sector 5, Block EP and GP,
Kolkata 700091, India.
Contact Number: +913346009199
Email Address: sales@sheeranalyticsandinsights.com

This release was published on openPR.